テキサスにおける急性骨髄性白血病の臨床試験
テキサス内の拠点で、急性骨髄性白血病に関する94件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07581002Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- MD Anderson Cancer Center, Houston
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT03629171A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06548230Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Houston
被験者募集中第3相
12歳以上 · 全性別 · 2026/09/25更新 · NCT07211958Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03874052Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03661307A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相健康なボランティア歓迎
12歳以上 · 全性別 · 2026/09/23更新 · NCT05360160Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06769490Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT03214562A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/18更新 · NCT06284486Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- M D Anderson Cancer Center, Houston
被験者募集中第1相
1歳以上 · 全性別 · 2026/09/18更新 · NCT03630991Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
- MD Anderson, Houston
被験者募集中第1相
12歳以上 · 全性別 · 2026/09/17更新 · NCT06786533A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他9件
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
被験者募集中第1相
75歳以下 · 全性別 · 2026/09/16更新 · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT03471260Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT03683433A Study of BGB-11417 in Participants With Myeloid Malignancies
- Md Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT04771130A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06616636A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06969430A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Children's Medical Center Dallas /ID# 275930, Dallas
被験者募集中第1相
6 Months – 17 Years · 全性別 · 2026/09/09更新 · NCT07306832ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT05010122Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他1件
被験者募集中第3相
1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/04更新 · NCT03383575A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- MD Anderson Cancer Center, Houston
被験者募集中第1相
2歳〜18歳 · 全性別 · 2026/09/04更新 · NCT06191978Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Baylor Scott & White Health, Dallas
- MD Anderson, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Dallas TX-SOUTHWESTERN, Dallas
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06652438CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳〜85歳 · 全性別 · 2026/08/26更新 · NCT06834282CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT04493164Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06533761Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06811233The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他10件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。